A Phase 1 interventional study of Zanubrutinib and Fluconazole in B-cell Malignancies, sponsored by BeiGene. Completed at 7 sites in Australia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-10-26.
Sponsored by BeiGene · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The primary objective of this study was to assess the steady-state zanubrutinib pharmacokinetics (PK) when co-administered with moderate and strong cytochrome P450 family 3 subfamily A (CYP3A) inhibitors.
BeiGene is the lead sponsor of 125 studies on the registry; 2 are open to participants now.
Of its 55 completed or terminated interventional studies of FDA-regulated products, 32 (58%) have results posted.
Counted across the registry records on this site, refreshed daily.
Key Inclusion Criteria:
Key Exclusion Criteria:
NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cycle 1 (30 days): Participants were administered zanubrutinib at a dose of 320 mg once a day from Day 1 to Day 3; From Day 4 to Day 10, fluconazole was administered once a day at a dose of 400 mg with zanubrutinib at a reduced dose of 80 mg twice a day; On Day 11 and Day 12, zanubrutinib monotherapy was administered at 80 mg twice a day, followed by 320 mg once a day from Day 13 to Day 21; From Day 22 to Day 28, diltiazem was administered once a day at a dose of 180 mg with 80 mg zanubrutinib twice a day; On Day 29 and Day 30, zanubrutinib monotherapy was administered 80 mg twice a day. Cycles 2 to 6 (28 days each cycle): Zanubrutinib 160 mg twice a day or 320 mg once a day.
Drug: Zanubrutinib · Drug: Fluconazole · Drug: Diltiazem
Cycle 1 (30 days): Participants were administered zanubrutinib at a dose of 320 mg once a day from Day 1 to Day 3; From Day 4 to Day 10, voriconazole was administered twice a day at a dose of 200 mg (total daily dose of 400 mg) with zanubrutinib at a reduced dose of 80 mg once a day; On Day 11 and Day 12, zanubrutinib monotherapy was administered at 80 mg once a day, followed by 320 mg once a day from Day 13 to Day 21; From Day 22 to Day 28, clarithromycin was administered twice a day at a dose of 250 mg (total daily dose of 500 mg) with 80 mg zanubrutinib once a day; On Day 29 and Day 30, zanubrutinib monotherapy was administered 80 mg once a day. Cycles 2 to 6 (28 days each cycle): Zanubrutinib 160 mg twice a day or 320 mg once a day.
Drug: Zanubrutinib · Drug: Voriconazole · Drug: Clarithromycin
Capsules administered at a dose and frequency as specified in the treatment arm
Also known as: BGB-3111, BRUKINSA
Capsules administered at a dose and frequency as specified in the treatment arm
Capsules administered at a dose and frequency as specified in the treatment arm
Capsules administered at a dose and frequency as specified in the treatment arm
Capsules administered at a dose and frequency as specified in the treatment arm
Arm A: Area Under Plasma Concentration-time Curve up to the Last Measurable Concentration (AUC0-t)
Time frame: Predose, 0.5, 1, 2, 3, 4, 6, 8 and 10 hours on Cycle 1 Day 3, Day 10, and Day 28 (30-day cycle)
Arm B: Area Under Plasma Concentration-time Curve up to the Last Measurable Concentration (AUC0-t)
Time frame: Predose, 0.5, 1, 2, 3, 4, 6, 8 and 10 hours on Cycle 1 Day 3, Day 10, and Day 28 (30-day cycle)
Arm A: Area Under Plasma Concentration-time Curve From Time 0 Extrapolated to 24 Hours (AUC0-24h)
Time frame: Predose, 0.5, 1, 2, 3, 4, 6, 8 and 10 hours on Cycle 1 Day 3, Day 10, and Day 28 (30-day cycle)
Arm B: Area Under Plasma Concentration-time Curve From Time 0 Extrapolated to 24 Hours (AUC0-24h)
Time frame: Predose, 0.5, 1, 2, 3, 4, 6, 8 and 10 hours on Cycle 1 Day 3, Day 10, and Day 28 (30-day cycle)
Arm A: Maximum Observed Concentration (Cmax)
Time frame: Predose, 0.5, 1, 2, 3, 4, 6, 8 and 10 hours on Cycle 1 Day 3, Day 10, and Day 28 (30-day cycle)
Arm B: Maximum Observed Concentration (Cmax)
Time frame: Predose, 0.5, 1, 2, 3, 4, 6, 8 and 10 hours on Cycle 1 Day 3, Day 10, and Day 28 (30-day cycle)
Arm A: Time of the Maximum Observed Concentration (Tmax)
Time frame: Predose, 0.5, 1, 2, 3, 4, 6, 8 and 10 hours on Cycle 1 Day 3, Day 10, and Day 28 (30-day cycle)
Arm B: Time of the Maximum Observed Concentration (Tmax)
Time frame: Predose, 0.5, 1, 2, 3, 4, 6, 8 and 10 hours on Cycle 1 Day 3, Day 10, and Day 28 (30-day cycle)
Arm A: Apparent Terminal Elimination Half-life (t1/2)
Time frame: Predose, 0.5, 1, 2, 3, 4, 6, 8 and 10 hours on Cycle 1 Day 3, Day 10, and Day 28 (30-day cycle)
Arm B: Apparent Terminal Elimination Half-life (t1/2)
Time frame: Predose, 0.5, 1, 2, 3, 4, 6, 8 and 10 hours on Cycle 1 Day 3, Day 10, and Day 28 (30-day cycle)
Number of Participants Experiencing Adverse Events (AEs)
Number of participants with treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs), including clinical laboratory tests
Time frame: From the date of first study drug administration to 30 days after last dose (up to approximately 15 months)
This study was conducted at 7 study centers in Australia.
| Milestone | Arm A: Zanubrutinib With or Without Moderate CYP3A | Arm B: Zanubrutinib With or Without Strong CYP3A |
|---|---|---|
| Started | 13 | 13 |
| Completed | 11 | 12 |
| Not completed | 2 | 1 |
| Withdrew: Physician decision | 1 | 1 |
| Withdrew: Death | 1 | 0 |
| h*ng/mL | Arm A: Zanubrutinib With or Without Moderate CYP3A |
|---|---|
| Zanubrutinib 320 mg QD | 1899.32 ± 44.95 |
| Zanubrutinib 80 mg BID + 400 mg fluconazole QD | 921.63 ± 45.80 |
| Zanubrutinib 80 mg BID + 180 mg diltiazem QD | 797.87 ± 43.05 |
| h*ng/mL | Arm B: Zanubrutinib With or Without Strong CYP3A |
|---|---|
| Zanubrutinib 320 mg QD | 1550.40 ± 49.20 |
| Zanubrutinib 80 mg QD + 200 mg voriconazole BID | 1254.29 ± 22.36 |
| Zanubrutinib 80 mg QD + 250 mg clarithromycin BID | 763.00 ± 54.79 |
| h*ng/mL | Arm A: Zanubrutinib With or Without Moderate CYP3A |
|---|---|
| Zanubrutinib 320 mg QD | 2035.32 ± 46.97 |
| Zanubrutinib 80 mg BID + 400 mg fluconazole QD | 1911.93 ± 46.97 |
| Zanubrutinib 80 mg BID + 180 mg diltiazem QD | 1653.07 ± 44.88 |
| h*ng/mL | Arm B: Zanubrutinib With or Without Strong CYP3A |
|---|---|
| Zanubrutinib 320 mg QD | 1578.12 ± 49.53 |
| Zanubrutinib 80 mg QD + 200 mg voriconazole BID | 1376.02 ± 25.09 |
| Zanubrutinib 80 mg QD + 250 mg clarithromycin BID | 766.71 ± 60.44 |
| ng/mL | Arm A: Zanubrutinib With or Without Moderate CYP3A |
|---|---|
| Zanubrutinib 320 mg QD | 520.78 ± 39.18 |
| Zanubrutinib 80 mg BID + 400 mg fluconazole QD | 235.72 ± 42.53 |
| Zanubrutinib 80 mg BID + 180 mg diltiazem QD | 211.06 ± 36.59 |
| ng/mL | Arm B: Zanubrutinib With or Without Strong CYP3A |
|---|---|
| Zanubrutinib 320 mg QD | 428.88 ± 43.56 |
| Zanubrutinib 80 mg QD + 200 mg voriconazole BID | 353.11 ± 30.23 |
| Zanubrutinib 80 mg QD + 250 mg clarithromycin BID | 215.15 ± 51.79 |
| Hours | Arm A: Zanubrutinib With or Without Moderate CYP3A |
|---|---|
| Zanubrutinib 320 mg QD | 2.03 (1.0 to 4.0) |
| Zanubrutinib 80 mg BID + 400 mg fluconazole QD | 2.93 (1.0 to 4.0) |
| Zanubrutinib 80 mg BID + 180 mg diltiazem QD | 2.05 (1.0 to 4.2) |
| Hours | Arm B: Zanubrutinib With or Without Strong CYP3A |
|---|---|
| Zanubrutinib 320 mg QD | 3.00 (1.0 to 4.0) |
| Zanubrutinib 80 mg QD + 200 mg voriconazole BID | 2.05 (1.0 to 3.9) |
| Zanubrutinib 80 mg QD + 250 mg clarithromycin BID | 2.08 (0.5 to 7.9) |
| Hours | Arm A: Zanubrutinib With or Without Moderate CYP3A |
|---|---|
| Zanubrutinib 320 mg QD | 2.15 (1.4 to 4.5) |
| Zanubrutinib 80 mg BID + 400 mg fluconazole QD | 2.10 (1.7 to 3.3) |
| Zanubrutinib 80 mg BID + 180 mg diltiazem QD | 2.14 (1.4 to 4.0) |
| Hours | Arm B: Zanubrutinib With or Without Strong CYP3A |
|---|---|
| Zanubrutinib 320 mg QD | 1.79 (1.2 to 2.5) |
| Zanubrutinib 80 mg QD + 200 mg voriconazole BID | 2.38 (1.6 to 2.8) |
| Zanubrutinib 80 mg QD + 250 mg clarithromycin BID | 2.08 (1.4 to 2.9) |
Number of participants with treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs), including clinical laboratory tests
| Participants | Arm A: Zanubrutinib With or Without Moderate CYP3A | Arm B: Zanubrutinib With or Without Strong CYP3A |
|---|---|---|
| At least one TEAE | 12 | 12 |
| At least one SAE | 3 | 1 |
Collected over From the date of first study drug administration to 30 days after last dose (up to approximately 15 months). Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Arm A: Zanubrutinib With or Without Moderate CYP3A | 1/13 (7.7%) | 3/13 (23.1%) | 12/13 (92.3%) |
| Arm B: Zanubrutinib With or Without Strong CYP3A | 0/13 (0%) | 1/13 (7.7%) | 12/13 (92.3%) |
| Event | Arm A: Zanubrutinib With or Without Moderate CYP3A | Arm B: Zanubrutinib With or Without Strong CYP3A |
|---|---|---|
| FallInjury, poisoning and procedural complications | 1/13 | 0/13 |
| Traumatic haemorrhageInjury, poisoning and procedural complications | 0/13 | 1/13 |
| Neck painMusculoskeletal and connective tissue disorders | 1/13 | 0/13 |
| Mantle cell lymphoma refractoryNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/13 | 0/13 |
| RadiculopathyNervous system disorders | 1/13 | 0/13 |
| Pneumonia cryptococcalInfections and infestations | 1/13 | 0/13 |
| Event | Arm A: Zanubrutinib With or Without Moderate CYP3A | Arm B: Zanubrutinib With or Without Strong CYP3A |
|---|---|---|
| ContusionInjury, poisoning and procedural complications | 3/13 | 4/13 |
| ConstipationGastrointestinal disorders | 1/13 | 3/13 |
| DiarrhoeaGastrointestinal disorders | 0/13 | 3/13 |
| Back painMusculoskeletal and connective tissue disorders | 2/13 | 3/13 |
| RashSkin and subcutaneous tissue disorders | 1/13 | 2/13 |
| Abdominal pain upperGastrointestinal disorders | 0/13 | 2/13 |
| FallInjury, poisoning and procedural complications | 1/13 | 2/13 |
| Musculoskeletal chest painMusculoskeletal and connective tissue disorders | 0/13 | 2/13 |
| Neck painMusculoskeletal and connective tissue disorders | 2/13 | 0/13 |
| NeutropeniaBlood and lymphatic system disorders | 2/13 | 2/13 |
| Age, Continuous(Years) | Arm A: Zanubrutinib With or Without Moderate CYP3A | Arm B: Zanubrutinib With or Without Strong CYP3A | Total |
|---|---|---|---|
| Mean | 70.5 ± 9.85 | 71.8 ± 8.64 | 71.1 ± 9.10 |
| Sex: Female, Male(Participants) | Arm A: Zanubrutinib With or Without Moderate CYP3A | Arm B: Zanubrutinib With or Without Strong CYP3A | Total |
|---|---|---|---|
| Female | 3 | 5 | 8 |
| Male | 10 | 8 | 18 |
| Ethnicity (NIH/OMB)(Participants) | Arm A: Zanubrutinib With or Without Moderate CYP3A | Arm B: Zanubrutinib With or Without Strong CYP3A | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 |
| Not Hispanic or Latino | 13 | 11 | 24 |
| Unknown or Not Reported | 0 | 2 | 2 |
| Race (NIH/OMB)(Participants) | Arm A: Zanubrutinib With or Without Moderate CYP3A | Arm B: Zanubrutinib With or Without Strong CYP3A | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 2 | 1 | 3 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 11 | 12 | 23 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes
Ran from Nov 2020 to primary completion in Feb 2022, 15 months.
Results were first posted in Nov 2023, 1 year 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Zanubrutinib